QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)

Syros Pharmaceuticals (SYRS) News Today

$7.09
+0.05 (+0.71%)
(As of 02/22/2024 ET)
SourceHeadline
MarketBeat logoVentyx Biosciences (NASDAQ:VTYX) and Syros Pharmaceuticals (NASDAQ:SYRS) Head-To-Head Contrast
americanbankingnews.com - February 22 at 1:38 AM
finance.yahoo.com logoSYRS Mar 2024 7.500 put
finance.yahoo.com - February 17 at 7:57 AM
MarketBeat logoSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded at StockNews.com
americanbankingnews.com - February 16 at 1:10 AM
marketbeat.com logoSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com
marketbeat.com - February 8 at 4:12 AM
marketbeat.com logoSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Sees Large Growth in Short Interest
marketbeat.com - January 29 at 9:43 AM
marketbeat.com logoSyros Pharmaceuticals (NASDAQ:SYRS) Lowered to Sell at StockNews.com
marketbeat.com - January 23 at 10:18 PM
thestreet.com logoSyros Pharmaceuticals Inc.
thestreet.com - January 23 at 10:12 AM
finance.yahoo.com logoAre You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
finance.yahoo.com - January 18 at 5:45 PM
finance.yahoo.com logoSyros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
finance.yahoo.com - January 17 at 4:44 PM
finance.yahoo.com logoWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
finance.yahoo.com - January 16 at 3:11 PM
finance.yahoo.com logoWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
finance.yahoo.com - January 16 at 3:11 PM
finance.yahoo.com logoWhat Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
finance.yahoo.com - January 16 at 3:11 PM
finance.yahoo.com logoWhy Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
finance.yahoo.com - January 11 at 1:43 PM
markets.businessinsider.com logoPositive Outlook for Syros Pharmaceuticals Backed by Strong Pipeline and Financial Health
markets.businessinsider.com - January 10 at 12:56 AM
finance.yahoo.com logoSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
finance.yahoo.com - January 8 at 12:03 PM
marketbeat.com logoQ1 2024 Earnings Forecast for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Issued By Brookline Capital Management
marketbeat.com - January 4 at 8:20 AM
finance.yahoo.com logoSteven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals
finance.yahoo.com - January 4 at 2:06 AM
marketbeat.com logoSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expected to Earn Q2 2024 Earnings of ($0.84) Per Share
marketbeat.com - January 3 at 6:34 AM
marketbeat.com logoInsider Buying: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Purchases 904,977 Shares of Stock
marketbeat.com - December 26 at 6:35 PM
markets.businessinsider.com logoThese Biotech Stocks Climbed To New Peaks - Did You Invest?
markets.businessinsider.com - December 26 at 9:56 AM
seekingalpha.com logoSyros prices capital raise of $45.0 million via securities offering
seekingalpha.com - December 19 at 10:13 AM
finance.yahoo.com logoSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
finance.yahoo.com - December 19 at 10:13 AM
finance.yahoo.com logoindividual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last week
finance.yahoo.com - December 13 at 10:17 AM
markets.businessinsider.com logoBuy Rating Justified by Syros Pharmaceuticals’ Strong Clinical Results and Market Potential
markets.businessinsider.com - December 7 at 2:44 PM
msn.com logoWhy Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?
msn.com - December 6 at 6:16 PM
msn.com logoSyros jumps after Phase 2 data for leukemia therapy
msn.com - December 6 at 6:16 PM
markets.businessinsider.com logoSyros Presents Positive Phase 2 Trial Data Of Tamibarotene Combination: Stock Up In Premarket
markets.businessinsider.com - December 6 at 12:49 PM
finance.yahoo.com logoSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
finance.yahoo.com - December 6 at 7:33 AM
markets.businessinsider.com logoPiper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
markets.businessinsider.com - November 16 at 10:42 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and Kiora Pharmaceuticals (KPRX)
markets.businessinsider.com - November 15 at 3:36 PM
finance.yahoo.com logoSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 15 at 3:36 PM
markets.businessinsider.com logoSyros Pharmaceuticals Q3 Loss misses estimates
markets.businessinsider.com - November 14 at 8:25 AM
finance.yahoo.com logoSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
finance.yahoo.com - November 14 at 8:25 AM
benzinga.com logoPreview: Syros Pharmaceuticals's Earnings
benzinga.com - November 13 at 4:18 PM
morningstar.com logoSyros Pharmaceuticals Inc SYRS
morningstar.com - November 12 at 8:29 PM
finance.yahoo.com logoSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
finance.yahoo.com - November 7 at 9:31 AM
bizjournals.com logoSyros CEO, chief scientist out as company cuts staff, programs
bizjournals.com - October 4 at 9:28 AM
marketwatch.com logoSyros Pharmaceuticals Shares Fall 18% on Staff Cuts, CEO Retirement
marketwatch.com - October 3 at 7:29 AM
marketwatch.com logoSyros Pharmaceuticals to Cut 35% of Staff; CEO Simonian to Retire
marketwatch.com - October 2 at 9:24 AM
finance.yahoo.com logoSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
finance.yahoo.com - October 2 at 9:24 AM
markets.businessinsider.com logoPiper Sandler Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)
markets.businessinsider.com - August 10 at 3:56 AM
markets.businessinsider.com logoSyros Pharmaceuticals (SYRS) Gets a Buy from H.C. Wainwright
markets.businessinsider.com - August 9 at 7:53 AM
finance.yahoo.com logoQ2 2023 Syros Pharmaceuticals Inc Earnings Call
finance.yahoo.com - August 9 at 2:53 AM
finance.yahoo.com logoSyros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 8 at 4:52 PM
finance.yahoo.com logoSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 8 at 10:29 AM
finance.yahoo.com logoSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
finance.yahoo.com - August 1 at 3:44 PM
benzinga.com logoPfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders
benzinga.com - July 24 at 9:34 AM
finance.yahoo.com logoPfizer to end license deal with Syros for blood disorder therapies
finance.yahoo.com - July 21 at 6:52 PM
msn.com logoSyros Pharmaceuticals (SYRS) Price Target Increased by 22.53% to 164.73
msn.com - July 6 at 8:32 PM
finance.yahoo.com logoSyros to Present at Sidoti June 2023 Virtual Small-Cap Conference
finance.yahoo.com - June 8 at 10:33 AM
Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.



SYRS Media Mentions By Week

SYRS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SYRS
News Sentiment

0.00

0.48

Average
Medical
News Sentiment

SYRS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SYRS Articles
This Week

3

1

SYRS Articles
Average Week

Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:SYRS) was last updated on 2/22/2024 by MarketBeat.com Staff